SCHEDULE 13G/A: Perceptive Advisors and Affiliates Disclose 2.5% Stake in Forte Biosciences

Perceptive Advisors LLC, along with Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd., has disclosed a 2.5% beneficial ownership stake in Forte Biosciences, Inc., as detailed in their latest Schedule 13G filing.

Summary

• Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. (collectively, the "Reporting Persons") have filed an Amendment No. 3 to Schedule 13G regarding their beneficial ownership in Forte Biosciences, Inc.
• The Reporting Persons collectively beneficially own 163,935 shares of Forte Biosciences, Inc. Common Stock.
• This ownership represents 2.5% of the Issuer's outstanding Common Stock.
• The calculation of the ownership percentage is based on an aggregate of 6,393,323 shares of Common Stock outstanding, as reported by Forte Biosciences in its Form 8-K filed with the SEC on January 24, 2025.
• Perceptive Life Sciences Master Fund, Ltd. directly holds 95,742 shares of Common Stock and pre-funded warrants immediately exercisable for 68,193 shares of Common Stock.
• Perceptive Advisors LLC serves as the investment manager to the Master Fund, and Joseph Edelman is the managing member of Perceptive Advisors LLC.
• The filing certifies that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a neutral, factual disclosure of beneficial ownership. It neither indicates overwhelmingly positive nor negative developments for the issuer, as it is a routine regulatory filing by an institutional investor.

Positives

• A notable institutional investor, Perceptive Advisors, maintains a stake in Forte Biosciences, potentially signaling continued confidence in the company's long-term prospects.

Negatives

• The filing does not indicate any significant increase or decrease in ownership that would suggest a strong positive or negative shift in investor sentiment, as it is an amendment to a previously disclosed stake.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the issuer's future performance or strategic direction.

Management Comments

• The document does not contain direct quotes or paraphrased statements from company management of Forte Biosciences, Inc. It includes certifications from Joseph Edelman as the managing member of Perceptive Advisors LLC and Perceptive Life Sciences Master Fund, Ltd., stating that the securities were not acquired for the purpose of changing or influencing control of the issuer.

Industry Context

This filing is a routine disclosure by an institutional investor in the biotechnology sector. Perceptive Advisors is a well-known investment firm specializing in life sciences, and their continued stake in Forte Biosciences aligns with their investment strategy in the industry. Such filings provide transparency on significant ownership stakes but do not typically reflect broader industry trends or competitive dynamics.

Comparison to Industry Standards

• As a routine Schedule 13G filing, this document primarily serves to disclose beneficial ownership and does not provide financial results or operational metrics that can be directly compared to industry benchmarks or specific comparable companies. The 2.5% stake is a passive investment, typical for institutional investors not seeking control, and is within the normal range for such disclosures.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional ownership stake, which can be a factor in assessing investor confidence and liquidity.

Next Steps

• The document does not outline any specific future actions, events, or milestones for Forte Biosciences, Inc. or the Reporting Persons beyond the regulatory filing itself.

Key Dates

Keywords

Forte Biosciences, Perceptive Advisors, Joseph Edelman, Perceptive Life Sciences Master Fund, Schedule 13G, Beneficial Ownership, Common Stock, Biotechnology Investment, Institutional Investor